Menu
A PhRMA funded report found that 340B drugs grew to 18% of total outpatient branded drug sales in 2022. The figures were criticized by 340B providers and others as misleading.

340B Drugs Reach 18% of Outpatient Drug Sales, Says PhRMA-Backed Research; Providers Say It is Misleading

Rich Daly, Editor in Chief 340B Report Views
340B drugs have steadily increased as a share of U.S. branded outpatient pharmaceutical sales and reached 18% of the total [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

340B Hospitals Should Consider Internal Pharmacies, Selective Contracting, Says Consulting Group

Novo Nordisk To Provide Refunds on Ozempic and Three Other Drugs to 340B Entities

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live